Investigational drug · Phase 2
JPI-547
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pancreatic Ductal Adenocarcinoma, Gastric Cancer (GC), Ovarian Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
6
Any phase or sponsor naming "JPI-547"
First trial start
2022
Mar 30, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JPI-547", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pancreatic Ductal Adenocarcinoma
- Gastric Cancer (GC)
- Ovarian Cancer
Approved drugs for the same conditions: Ovarian cancer · Pancreatic cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "JPI-547" as an intervention, largest first.
- To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian CancerNot yet recruiting
Onconic Therapeutics Inc.Industry
NCT07370818 · 81 participants (planned) · Start Feb 27, 2026 · Primary completion Dec 31, 2029
Drug: JPI-547; Bevacizumab · For: Ovarian Cancer
Sites: Seoul, South Korea
Onconic Therapeutics Inc.Industry
NCT05257993 · 71 participants (planned) · Start Mar 30, 2022 · Primary completion Apr 2030
Drug: JPI-547; modified FOLFIRINOX and 1 more · For: Pancreatic Ductal Adenocarcinoma
Sites: Gyeonggi-do, South Korea; Seoul, South Korea · 4 sites in all
Onconic Therapeutics Inc.Industry
NCT04335604 · 62 participants · Start Dec 6, 2017 · Primary completion Dec 14, 2021
Drug: JPI-547 · For: Advanced Solid Tumors
Sites: Seongnam-si, South Korea; Seoul, South Korea
Onconic Therapeutics Inc.Industry
NCT05475184 · 58 participants (planned) · Start Aug 31, 2022 · Primary completion Nov 2024
Drug: JPI-547 · For: Ovarian Cancer
Sites: Gyeonggi-do, South Korea
- To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric CancerNot yet recruiting
Onconic Therapeutics Inc.Industry
NCT07364422 · 49 participants (planned) · Start Feb 27, 2026 · Primary completion Feb 28, 2026
Drug: JPI-547; Irinotecan (drug) · For: Gastric Cancer (GC)
Sites: Seoul, South Korea
- Food and Ethnicity Effects on Pharmacokinetics and Safety of JPI-547 in Healthy Male ParticipantsNot yet recruiting
Onconic Therapeutics Inc.Industry
NCT07570186 · 36 participants (planned) · Start May 2026 · Primary completion Jul 2026
Drug: JPI-547 · For: Healthy Volunteers
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
- JPI-547, a novel dual inhibitor of PARP1/2 and tankyrase is more effective than first-generation PARP inhibitors in preclinical BRCA1/2-mutated cancer models.
Kang MS, Katuwal NB, Ghosh M, et al. · Br J Cancer 2026
- Dual PARP/Tankyrase Inhibition Enhances Antitumor Efficacy in PTEN-Deficient Endometrial Cancer.
Kang SW, Eum H, Lee JY, et al. · J Cell Mol Med 2026
- JPI-547, a Dual Inhibitor of PARP/Tankyrase, Shows Antitumor Activity Against Pancreatic Cancers with Homologous Recombination Repair Deficiency or Wnt-Addiction.
Oh KS, Nam AR, Bang JH, et al. · Int J Biol Sci 2025
Also in development for Pancreatic Ductal Adenocarcinoma
- AZD0901Sonesitatug vedotin, CMG901Phase 36 trials
AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma
- Supportive care measuresPhase 36 trials
Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
- AtebimetinibIMM-1-104, Group APhase 34 trials
Immuneering Corporation · Pancreatic Adenocarcinoma, Advanced Solid Tumor, Malignant Melanoma (Cutaneous)
- IBI343Arcotatug TavatecanPhase 34 trials
Innovent Biologics (Suzhou) Co. Ltd. · CLDN18.2 Positive, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Primary Gastric Adenocarcinoma
- NavlimetostatBMS-986504, MRTX1719Phase 34 trials
Bristol Myers Squibb · Pancreatic Ductal Adenocarcinoma, Metastatic Non-small Cell Lung Cancer With MTAP Deletion, Solid Tumors
- [18F]FAPI-74 PETPhase 33 trials
SOFIE · Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction
- ChiauranibCS2164Phase 33 trials
Chipscreen Biosciences, Ltd. · Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma
- SBP-101ivospeminPhase 31 trial
Panbela Therapeutics, Inc. · Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.